派姆单抗致甲状腺功能减退1例

Q4 Medicine

Japanese Journal of Head and Neck Cancer Pub Date : 2022-01-01 DOI:10.5981/jjhnc.48.295

Keitaro Fujii, T. Imai, Yuya Miyakura, Kohsei Hasegawa, Akira Nakazato, Shinkichi Morita, Satoshi Saijyo, Y. Asada

{"title":"派姆单抗致甲状腺功能减退1例","authors":"Keitaro Fujii, T. Imai, Yuya Miyakura, Kohsei Hasegawa, Akira Nakazato, Shinkichi Morita, Satoshi Saijyo, Y. Asada","doi":"10.5981/jjhnc.48.295","DOIUrl":null,"url":null,"abstract":"subsequent to hypothyroidism: A 60-year-old man was treated with pembrolizumab for recurrence of lung metastasis after surgery for hy-popharyngeal carcinoma. Three months after the first dose, severe hypothyroidism was observed. This was thought to be an immune-related adverse event （irAE） and treatment was temporarily discontinued. Levothy-roxine was started, thyroid function recovered, and pembrolizumab was restarted. Seven months after the first dose, general malaise and anorexia were observed. On the basis of the decrease in serum ACTH and cortisol levels, we diagnosed hypopituitarism as an irAE. Hydrocortisone was administered and the general condition promptly improved. Hypothyroidism induced by immune checkpoint inhibitors is a frequently observed irAE and may be secondary to hypopituitarism, as in this case.","PeriodicalId":38497,"journal":{"name":"Japanese Journal of Head and Neck Cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism\",\"authors\":\"Keitaro Fujii, T. Imai, Yuya Miyakura, Kohsei Hasegawa, Akira Nakazato, Shinkichi Morita, Satoshi Saijyo, Y. Asada\",\"doi\":\"10.5981/jjhnc.48.295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"subsequent to hypothyroidism: A 60-year-old man was treated with pembrolizumab for recurrence of lung metastasis after surgery for hy-popharyngeal carcinoma. Three months after the first dose, severe hypothyroidism was observed. This was thought to be an immune-related adverse event （irAE） and treatment was temporarily discontinued. Levothy-roxine was started, thyroid function recovered, and pembrolizumab was restarted. Seven months after the first dose, general malaise and anorexia were observed. On the basis of the decrease in serum ACTH and cortisol levels, we diagnosed hypopituitarism as an irAE. Hydrocortisone was administered and the general condition promptly improved. Hypothyroidism induced by immune checkpoint inhibitors is a frequently observed irAE and may be secondary to hypopituitarism, as in this case.\",\"PeriodicalId\":38497,\"journal\":{\"name\":\"Japanese Journal of Head and Neck Cancer\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Head and Neck Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5981/jjhnc.48.295\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Head and Neck Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5981/jjhnc.48.295","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

甲状腺功能减退:一名60岁男性接受派姆单抗治疗下咽癌手术后肺转移复发。第一次给药后3个月出现严重的甲状腺功能减退。这被认为是一种免疫相关不良事件(irAE)，因此暂时停止治疗。开始使用左旋素，甲状腺功能恢复，重新使用派姆单抗。第一次给药后7个月，观察到全身不适和厌食。根据血清ACTH和皮质醇水平的下降，我们将垂体功能减退诊断为rae。给予氢化可的松，一般情况迅速改善。免疫检查点抑制剂引起的甲状腺功能减退是一种常见的irAE，可能继发于垂体功能减退，如本例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism

subsequent to hypothyroidism: A 60-year-old man was treated with pembrolizumab for recurrence of lung metastasis after surgery for hy-popharyngeal carcinoma. Three months after the first dose, severe hypothyroidism was observed. This was thought to be an immune-related adverse event （irAE） and treatment was temporarily discontinued. Levothy-roxine was started, thyroid function recovered, and pembrolizumab was restarted. Seven months after the first dose, general malaise and anorexia were observed. On the basis of the decrease in serum ACTH and cortisol levels, we diagnosed hypopituitarism as an irAE. Hydrocortisone was administered and the general condition promptly improved. Hypothyroidism induced by immune checkpoint inhibitors is a frequently observed irAE and may be secondary to hypopituitarism, as in this case.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Japanese Journal of Head and Neck Cancer Medicine-Otorhinolaryngology

CiteScore

0.10

自引率

0.00%

发文量